Back to Stocks

CCTC

Catalyst Crew Technologies Corp.
7 filings tracked
healthcarehealthcare technologyMICRO (<$300M)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Catalyst Crew Technologies is attempting a comprehensive corporate rebirth, pivoting from a dormant legacy entity into a focused AI-driven healthcare provider.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of an AI pivot, Catalyst Crew Technologies remains a pre-revenue entity with a precarious financial foundation.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CCTC filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The 10-K filing reveals a company at a critical crossroads, transitioning from a shell-like state to a development-stage AI healthcare venture. The successful execution of this pivot depends entirely on the company's ability to secure immediate funding and clinically validate its AI platforms. While the reduction in burn rate is a positive sign of operational tightening, the lack of liquidity and the presence of material weaknesses in financial reporting are significant red flags that cannot be ignored. Ultimately, Catalyst Crew is a high-risk, high-reward play on the intersection of AI and emerging market healthcare. The upside is tied to the potential for the CardioAI, PulmoAI, and NeuroAI platforms to disrupt clinical workflows in Latin America. However, the downside is a potential total loss of capital driven by a failure to raise funds or the collapse of operations due to Venezuelan geopolitical volatility. Investors are essentially betting on the personal expertise of Dr. Levy and the viability of a business model that currently lacks both revenue and a functional balance sheet.

Selected Quarter

Core Takeaway

The company has pivoted to AI healthcare with a new CEO and lean cost structure, but it lacks cash and faces a 'going concern' warning from auditors.

Investor Lens

The trade-off is between the asymmetric upside of a successful AI healthcare launch and the very high probability of insolvency or total dilution.

Watch Next

Any announcement of a new funding round or clinical validation results for the AI platforms.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.12Q2 '26 (10-K)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-K)
bullishMay 4

Operating expenses decreased by over 90% year-over-year.

margin expansion
70%
neutralMay 4

Raised $150,200 through the issuance of 15 million shares in 2025.

capital raise
40%
bullishMay 4

New leadership under Dr. Kevin Rodan Levy aligns clinical expertise with AI strategy.

management change
60%
bearishMay 4

Significant dilution from asset purchase and ongoing need for equity financing.

dilution risk
80%
bullishMay 4

Operating expenses decreased by over 90% year-over-year.

margin expansion
70%
neutralMay 4

Raised $150,200 through the issuance of 15 million shares in 2025.

capital raise
40%
bullishMay 4

New leadership under Dr. Kevin Rodan Levy aligns clinical expertise with AI strategy.

management change
60%
bearishMay 4

Significant dilution from asset purchase and ongoing need for equity financing.

dilution risk
80%
bullishMay 4

Operating expenses decreased by over 90% year-over-year.

margin expansion
70%
neutralMay 4

Raised $150,200 through the issuance of 15 million shares in 2025.

capital raise
40%
bullishMay 4

New leadership under Dr. Kevin Rodan Levy aligns clinical expertise with AI strategy.

management change
60%
bearishMay 4

Significant dilution from asset purchase and ongoing need for equity financing.

dilution risk
80%
bullishMay 4

Operating expenses decreased by over 90% year-over-year.

margin expansion
70%
neutralMay 4

Raised $150,200 through the issuance of 15 million shares in 2025.

capital raise
40%
bullishMay 4

New leadership under Dr. Kevin Rodan Levy aligns clinical expertise with AI strategy.

management change
60%
bearishMay 4

Significant dilution from asset purchase and ongoing need for equity financing.

dilution risk
80%
bullishMay 4

Operating expenses decreased by over 90% year-over-year.

margin expansion
70%
neutralMay 4

Raised $150,200 through the issuance of 15 million shares in 2025.

capital raise
40%
bullishMay 4

New leadership under Dr. Kevin Rodan Levy aligns clinical expertise with AI strategy.

management change
60%
bearishMay 4

Significant dilution from asset purchase and ongoing need for equity financing.

dilution risk
80%
bullishMay 4

Operating expenses decreased by over 90% year-over-year.

margin expansion
70%
neutralMay 4

Raised $150,200 through the issuance of 15 million shares in 2025.

capital raise
40%
bullishMay 4

New leadership under Dr. Kevin Rodan Levy aligns clinical expertise with AI strategy.

management change
60%
bearishMay 4

Significant dilution from asset purchase and ongoing need for equity financing.

dilution risk
80%
bullishMay 4

Operating expenses decreased by over 90% year-over-year.

margin expansion
70%
neutralMay 4

Raised $150,200 through the issuance of 15 million shares in 2025.

capital raise
40%
bullishMay 4

New leadership under Dr. Kevin Rodan Levy aligns clinical expertise with AI strategy.

management change
60%
bearishMay 4

Significant dilution from asset purchase and ongoing need for equity financing.

dilution risk
80%

Filing History

10-KMay 4, 2026
Expand Sequence

The 10-K filing reveals a company at a critical crossroads, transitioning from a shell-like state to a development-stage AI healthcare venture. The successful execution of this pivot depends entirely on the company's ability to secure immediate funding and clinically validate its AI platforms. While the reduction in burn rate is a positive sign of operational tightening, the lack of liquidity and the presence of material weaknesses in financial reporting are significant red flags that cannot be ignored. Ultimately, Catalyst Crew is a high-risk, high-reward play on the intersection of AI and emerging market healthcare. The upside is tied to the potential for the CardioAI, PulmoAI, and NeuroAI platforms to disrupt clinical workflows in Latin America. However, the downside is a potential total loss of capital driven by a failure to raise funds or the collapse of operations due to Venezuelan geopolitical volatility. Investors are essentially betting on the personal expertise of Dr. Levy and the viability of a business model that currently lacks both revenue and a functional balance sheet.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.